Pharmamarketeer

Latest articles

Novavax COVID-19 vaccine meets trial endpoints

Novavax has announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness endpoint in the paediatric expansion of its PREVENT-19 pivotal Phase 3 trial. The...

Medhc-fases-banner
Advertentie(s)